(Q40349386)

19 September 2017

title

So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics (English)

1 reference

19 September 2017

1 reference

J Andrew Williams

1

1 reference

19 September 2017

Keith Johnson

series ordinal

2

1 reference

19 September 2017

Joseph Paulauskis

series ordinal

3

1 reference

19 September 2017

Jack Cook

series ordinal

4

1 reference

19 September 2017

publication date

1 March 2006

1 reference

The Journal of Clinical Pharmacology

19 September 2017

published in

1 reference

19 September 2017

volume

46

1 reference

19 September 2017

issue

3

1 reference

19 September 2017

page(s)

258-264

1 reference

The regulation of pharmacogenomics-based drugs and policy making.

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

The MDR1 (ABCB1) gene polymorphism and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Clinical aspects of the MDR1 (ABCB1) gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

ABCG2 -- a transporter for all seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Reaction phenotyping in drug discovery: moving forward with confidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Truncated area under the curve as a measure of relative extent of bioavailability: evaluation using experimental data and Monte Carlo simulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005283463

21 January 2018

Identifiers

DOI

10.1177/0091270005283463

1 reference

19 September 2017

1 reference